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Two types of serological assays are commonly used for the assessment of pertussis vaccine-induced
antibodies; the Chinese hamster ovary cell (CHO cell) assay and the immunoglobulin G (IgG) anti
pertussis toxin (PT) enzyme-linked immunosorbent assay (IgG anti-PT ELISA). Recently, both the
techniques have been modiﬁed to improve performance with sera with interfering activity (CHO cell
assay) or with heat-treated sera (IgG anti-PT ELISA). These two improved techniques were compared
by the analysis of 100 individual serum samples from a previous clinical trial and 213 sera from a longi-
tudinal serum collection from 20 Danish adults recently vaccinated with the Danish acellular pertussis
vaccine. The comparison showed a signiﬁcant linear correlation between the results of the two assays
with a p-value of <0.0001 for the 100 individual samples. We, therefore, conclude that the improved
IgG anti-PT ELISA can be used as a replacement for the often troublesome and time-consuming CHO
cell assay for the measurement of vaccine-induced human antibodies to PT.
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In clinical trials of pertussis vaccines, the
induced pertussis antibodies are often measured
using both an indirect immunoglobulin G (IgG)
antipertussistoxin(PT)enzyme-linkedimmuno-
sorbent assay (IgG anti-PT ELISA) and a Chi-
nese hamster ovary cell (CHO cell) assay (1–3).
Both the methods quantify the binding of
human antibodies to PT, but the molecular abil-
ities of the measured antibodies are diﬀerent,
and the antibody-binding sites could possibly be
diﬀerent as well. Thus, in the IgG anti-PT
ELISA, the PT is immobilized on a plastic
surface and the amount of human IgG anti-
bodies binding to the toxin is measured
colorimetrically (4). In the CHO cell assay,
neutralization of the biological activity of the
PT by human antibodies is evaluated by the
inhibition of toxin-mediated clustering of CHO
cells (5). In the IgG anti-PT ELISA, the anti-PT
antibodies are quantiﬁed by automated reading
of the amount of produced colour, whereas in
the CHO cell assay, the neutralizing anti-PT
antibodies are quantiﬁed by the use of a dilution
series and evaluation of the clustering of the
CHO cells by microscopy.
IgG anti-PT ELISA is also frequently used
for diagnostic and seroepidemiological purposes
(6, 7) and the CHO cell assay is also used for
potency testing of pertussis vaccines (8) and for
the analysis of residual toxicity in pertussis tox-
oid vaccines (9).
In a routine diagnostic setting, IgG anti-PT
ELISA is easy to perform and a large number of
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968samples can be analysed simultaneously and
automatically. Moreover, the availability of an
international standard serum (10) has made
standardizations of the assay possible. The
CHO cell assay, however, is time consuming
compared with the IgG anti-PT ELISA, and
being an assay involving living cells, fairly large
day-to-day variations may occur. The results
from the CHO cell assay are dependent on the
toxicity of the PT used in the assay (11), and so
far, a common standard for PT preparations is
not available (12).
Previous studies have shown a good correla-
tion between the IgG anti-PT ELISA and the
CHO cell assay (2, 10, 13–18). However, both
the IgG anti-PT ELISA and the CHO cell assay
have been altered recently. The CHO cell assay
was improved by precoating of microplates with
foetal calf serum to avoid problems occurring
from sera with interfering activity (5). The IgG
anti-PT ELISA was improved by addition of a
blocking step including powdered skimmed milk
to avoid problems occurring when heat-treated
sera were tested (4).
In this study, we compared these two recently
altered analyses to establish whether the
improved IgG anti-PT ELISA can replace the
CHO cell assay for quantiﬁcation of vaccine-
induced human antibodies to PT.
MATERIALS AND METHODS
Serum samples
A total of 100 serum samples from a previous clinical
trial of pertussis combination vaccines (19) were
selected according to previously measured CHO cell
assay results to represent a broad range of anti-PT
titres. In addition, 213 sera from 20 Danish adults
who were recently vaccinated with a combination vac-
cine including acellular PT (DiTeKiPol Booster, Sta-
tens Serum Institut, Copenhagen, Denmark) were
analysed; 4–13 samples were available from each of
those 20 individuals (20).
CHO cell assay
The CHO cell assay was performed as described by
Østerga ˚ rd et al. (5). In brief, 50 lL of a dilution series
of serum (1:2 to 1:4096) was mixed with 0.25 ng of PT
(Statens Serum Institut, Copenhagen, Denmark) in a
microplate and subsequently, 100 lL of CHO cells in
culture medium (1 · 10
5 cells⁄mL) was added. After
incubation, the plates were dried and dyed and
clustering of the cells was evaluated microscopically.
To avoid interfering activity from frozen samples, the
microplates were precoated with 40% foetal calf
serum. Results are expressed in titres as the reciprocal
of the highest serum dilution resulting in 100% neu-
tralization of the clustering eﬀect of the toxin.
Enzyme-linked immunosorbent assay
The IgG anti-PT ELISA assay is an in-house devel-
oped assay described previously (4). In brief, the assay
is an indirect ELISA using 0.2 lg⁄mL of PT as coat-
ing antigen. Sera were analysed in a 1000-fold dilu-
tion, and IgG results were expressed as IU⁄mL
according to the WHO International Standard Per-
tussis Antiserum (National Institute for Biological
Standards and Control, Potters Bar, UK, code:
06⁄140). To avoid false-positive results from heat-
treated sera, 1% powdered skimmed milk was
included in the blocking buﬀer and 0.1% powdered
skimmed milk was included in the sample dilution
buﬀer.
Statistical analysis
Results from the CHO cell assay were compared with
results from the IgG anti-PT ELISA assay using
Pearson’s product moment correlation coeﬃcient on
log10-transformed values. This statistical analysis was
calculated only for the 100 individual samples, as the
213 additional samples from the 20 vaccinated per-
sons were not independent.
RESULTS
When comparing the two analyses, the results
are clearly correlated (Fig. 1). The data from
the 313 samples tested showed a very good cor-
relation between the two methods, and only a
few outliers were observed.
A statistical analysis of the 100 independent
samples gave a correlation factor of 0.80 with a
p-value of <0.0001.
DISCUSSION
Human antibodies against PT are convention-
ally measured by two very diﬀerent methods:
the CHO cell assay and the IgG anti-PT ELISA.
The CHO cell assay is based on the detection of
toxin-neutralizing antibodies, whereas the
ELISA measures the direct binding of antibody
to the toxin. However, antibody titres obtained
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This correlation has previously been shown for
pertussis toxin antibodies induced by acellular
pertussis vaccination (2, 13, 14, 17, 21), by
whole-cell pertussis vaccination (14), by Borde-
tella pertussis infections (16) and in general (10,
18).
Both methods have been modiﬁed during the
years; nevertheless, our study shows that the
correlation was seemingly unaﬀected. Diverging
results were observed for a few sera, and both
combinations of a high result in one assay and a
low result in the other assay were seen. Such
aberrant results have also been observed previ-
ously (14), and the reason for this remains
unknown. The general practical diﬃculties of
the CHO cell assay could, however, be a likely
explanation.
The CHO cell assay and the IgG anti-PT
ELISA were seen to produce correlating results.
Although the mechanisms behind the two meth-
ods are very diﬀerent, both involve the binding
of speciﬁc antibodies to PT. In the case of IgG
anti-PT ELISA, only IgG antibodies binding
directly to the adsorbed PT are measured,
whereas the binding of IgA or IgM is not. In the
CHO cell assay, the antibodies should not only
bind to the toxin, but also neutralize the eﬀect of
the toxin in clustering of the CHO cells. Thus,
the avidity and function of the antibodies play
an important role in the CHO cell assay, but the
assay does neither measure the amount of anti-
bodies nor assess the class of antibodies involved
in the neutralization. The observed correlation
between the two methods could imply that IgG
is either the major factor contributing to neu-
tralization, or that the induced PT antibodies
are predominantly of the IgG class. The latter
hypothesis is underlined by results from studies
of both whole-cell and acellular pertussis vac-
cines showing either a missing or a modest post-
vaccination increase in IgA anti-PT antibodies
compared with the increase in IgG anti-PT anti-
bodies (21–25). Moreover, the IgM anti-PT
response was found to be negligible both after
acellular pertussis vaccination (22) and after
whole-cell pertussis vaccination (25).
The correlation between the CHO cell assay
and the IgG anti-PT ELISA has also been
shown using sera from individuals with con-
ﬁrmed B. pertussis infection (16), where the
immune response include not only IgG, but also
IgA and IgM (26, 27). However, after natural
infection, the IgG anti-PT infection response
has been shown to be stronger in comparison
with the IgA and IgM responses (28). Thus, it
would seem that the PT neutralization eﬀect at
the CHO cell assay is mainly because of IgG
anti-PT antibodies – either because of a speciﬁc
function of the IgG anti-PT antibodies, or
because of the major presence of IgG anti-PT in
comparison with IgM and IgA anti-PT antibod-
ies both after pertussis vaccination and after
pertussis infection. The CHO cell assay using
human serum has been tested previously for use
as a diagnostic tool for pertussis, but it was con-
cluded that an ELISA was more sensitive (16).
A diﬀerent approach using the CHO cell assay
for pertussis diagnosis based on nasopharyngeal
secretions has also been reported (29). In this
study, only post-vaccination sera were tested as
the CHO cell assay with human serum is now
only used for assessment of post-vaccination
antibody responses.
CONCLUSION
In this study, we show that the measurement of
human post-vaccination antibodies against PT
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Fig. 1. Correlation between immunoglobulin G anti
pertussis toxin enzyme-linked immunosorbent assay
and Chinese hamster ovary cell assay. Black squares
indicate samples from 100 individuals. Grey circles
indicate 213 samples from 20 individuals.
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similar results: the IgG anti-PT ELISA measur-
ing the antibody quantity as IU⁄mL and the
CHO cell assay measuring the antibody quan-
tity as arbitrary antibody titres. When compar-
ing the practical aspects of the two methods, the
IgG anti-PT ELISA is by far the easiest, fastest
and most reproducible method. Moreover,
results from IgG anti-PT ELISA can be stan-
dardized using the WHO International Stan-
dard Serum (10), whereas there is currently no
standardization consensus of the CHO cell
assay (11, 12). Therefore, when assessing vac-
cine-induced human antibodies to PT, IgG anti-
PT ELISA should be preferred over the CHO
cell assay.
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